Upload
trinhthuy
View
223
Download
0
Embed Size (px)
Citation preview
19Aprile2017 PaolaRogliani
PAOLAROGLIANI
ProfessoreAssociato
Malattiedell'ApparatoRespiratorio-MED/10-
DipartimentodiMedicinadeiSistemi
UniversitàdiRoma“TorVergata”
ViaMontpellier,1–00133-Roma,Italia
Luogodinascita Napoli
Datadinascita 19-09-1970
Cittadinanza Italiana
Statocivile Coniugata
• Direttore della di Scuola di Specializzazione in “Malattie dell’Apparato Respiratorio”,
DipartimentodiMedicinadeiSistemi,UniversitàdegliStudidiRoma“TorVergata”.
• Direttore (ff) della UOC di Malattie dell’Apparato Respiratorio, Dipartimento Clinico di
Medicina,“PoliclinicoTorVergata”Roma.
19Aprile2017 PaolaRogliani
Luglio1988 MaturitàClassicaconilmassimodeivoti.
Ottobre1994 LaureainMedicinaeChirurgiapressol’UniversitàdeglistudidiRoma“TorVergata”con110/110elode.
Dicembre1994 Abilitazioneall’eserciziodellaprofessionemedico-chirurgicanellapressolaSecondaUniversitàdeglistudidiNapolicon90/90.
Novembre1998 Specializzazionein“Malattiedell’ApparatoRespiratorio”pressol’UniversitàdeglistudidiRoma“TorVergata”con50/50elode.
Gennaio1999 BorsadiStudiodiPerfezionamentoall’estero-legge398/89-areadisciplinaregruppoB(ScienzeMedicheApplicate),gen-dic1999.
Novembre1999 Ricercatoreperilsettorescientifico-disciplinareMED/10,Malattiedell’ApparatoRespiratorio,pressolaFacoltàdiMedicinaeChirurgiadell’UniversitàdegliStudidiRoma“TorVergata”.
Luglio2006 Attribuzionecondecretorettoraledeltitolodi“ProfessoreAggregato”.
Dicembre2012 ProfessoreAssociatononconfermato,MED/10,Malattiedell’ApparatoRespiratorio,pressolaFacoltàdiMedicinaeChirurgiadell’UniversitàdegliStudidiRoma“TorVergata”,DipartimentodiMedicinadeiSistemi.
2013-2015 Direttore/CoordinatoreScuoladiSpecializzazioneinMedicinadelleSport,UniversitàdegliStudidiRoma“TorVergata”
2015-presente Direttore/CoordinatoreScuoladiSpecializzazionein“Malattiedell’ApparatoRespiratorio”,UniversitàdegliStudidiRoma“TorVergata”
AttivitàScientificaediRicerca
Nov/1989-Nov/1991 InternapressoilDipartimentodiBiochimicaeBiofisica“F.Cetrangolo”dellaSecondaUniversitàdeglistudidiNapolidirettadalProf.GennaroDellaPietra.
Gen/1994-Dic/1996 Internapressoillaboratoriodi“Cardiologiamolecolareecellulare”dell’UniversitàdeglistudidiRoma“TorVergata”direttodalDr.PaoloDiNardo.
Gen/1997-Dic/1998 VisitingFellowpressolaPulmonaryandCriticalCareMedicineBranch,pressol’NHLBIdell’NationalInstituteofHealth(NIH)Bethesda,MD–USA-direttadalDr.JoelMoss.
19Aprile2017 PaolaRogliani
Gen/1999-Ago/2000 VisitingFellowpressoil“LaboratoryofMolecularImmunology”,pressol’NHLBIdell’NationalInstituteofHealth(NIH)Bethesda,MD–USA-direttodalDrWarrenJLeonard.
Sett/2000-Dic/2012 RicercatorenelgruppodisciplinareMED10"Malattiedell’ApparatoRespiratorio”,DipartimentodiMedicinaInterna,UniversitàdeglistudidiRoma“TorVergata”.
Dic/2012-presente ProfessoreAssociatonelgruppodisciplinareMED10"Malattiedell’ApparatoRespiratorio”,DipartimentodiMedicinadeiSistemi,UniversitàdeglistudidiRoma“TorVergata”.
LINEEdiRICERCA
• Patologiaostruttivaedismetabolismo
• Lecomorbilitànellapatologiaostruttivabronchialecronica(asmaeBPCO):epidemiologiaepossibilimeccanismipatogenetici.
• Valutazionepreclinicaeclinicadeinuovifarmaciperiltrattamentodellapatologiaostruttivabronchialecronica(BPCOeasma).
• Basistrutturaliefunzionalidellasuscettibilitàgeneticaallepatologieinterstizialipolmonari
• Enfisemapolmonare:a1-Antitripsinaeilsuoruoloinibitoredell’elastasineutrofila.
PREMI/AWARD
2010 PremioMigliorricercatoreunder40dell’XI°CongressoNazionaledellaPneumologia
COMITATIEDITORIALI
2013-presente EditorialBoardofArsPneumologica
2013-presente EditorialBoardofCOPDResearchandPractice
2015-presente EditorialBoardofPulmonaryPharmacologyandTherapeutics
2015-presente EditorialBoardofJournalofPulmonologyandRespiratoryResearch
2016-presente EditorialBoardofInternationalJournalofChronicObstructivePulmonaryDisease
19Aprile2017 PaolaRogliani
SOCIETA’SCIENTIFICHE
• Sociodell’EuropeanRespiratorySociety(ERS)
• SociodellaSocietàItalianadiMedicinaRespiratoria(SIMeR),SegretarioelettoGruppoClinicamandato2016/2018
COLLABORAZIONISCIENTIFICHE
2007-Presente CollaborazionediricercaconilSacklerInstituteofPulmonaryPharmacology,King’sCollegeLondon,profClivePage.
2007-Presente CollaborazionediricercaconlaSezionediFarmacologiaLeonardoDonatelli,DipartimentodiMedicinaSperimentaleFacoltàdiMedicinaeChirurgiaIIUniversitàdegliStudidiNapoli“Vanvitelli”,Prof.ssaMariaGabriellaMatera
2008-Presente CollaborazionediricercaconlaDivisionofRespirology,WesternUniversity,London,Ontario,Canada,ProfMarcoMura.
2010-Presente CollaborazionediricercaconleMalattieRespiratorieeTrapiantoPolmonare,UniversitàdiSiena,Prof.ssaPaolaRottoli
PARTECIPAZIONEAUNITÀOPERATIVEDIRICERCA
- Componentedell’unitàdiricercadelprogetto“Geneticadellacardiomiopatiaipertrofica“GrantCNR92.0330711,9303391.11
- Componentedell’unitàdiricercadelprogetto“RoleofNitricOxideinthepathogenesisoflungdisease”GrantNIH201HL02537.04PCCMB
- Componentedell’unitàdiricercadelprogetto“AnalysisofHLA-DPassociationwithberylliumdiseasesusceptibilityinpooledexposedpopulation”GrantDE-FG02-02ER63416
- Componentedell’unitàdiricercadelprogetto“RoleofpeptidebindingandintracellularsignallingdiversityofmajorhistocompatibilitycomplexgenesinT-cellactivationanddifferentiationinchronicgranulomatousdisorders”Grant(ISS-NIH)CONV.N.530/F-A15
- Componetedell’unitàdiricercadelprogetto“IdentificazionedegliagretopiperigenidelComplessoMaggiorediIstocompatibilitàdiclasseIIcoinvoltinellasuscettibilitàallasarcoidosienellaevoluzionefibroticadellamalattia”PRIN2004067923_006
- ResponsabilediUnitàOperativadiricercadelprogetto“PiattaformaItalianaperlostudiodelle polimorbilità: scenario epidimiologico, aspetti clinici e farmacologici, prospettiva digenereecontestofarmaco-economico”,ISSPROGRAMMACCM2012
19Aprile2017 PaolaRogliani
- Componetedell’unitàdiricercadelprogettodell’UniversitàdiRomaTorVergata,ProgettoMIUR Smart Cities: Smart domotics for safe and energy-aware assisted living – SEAL:Smart&safe,Energy-awareAssistedLiving,incollaborazioneconElicas.p.a.,BFTs.p.a.ecc.(2013)
- Project director in the research program on "Pharmacological investigation of theinteractionbetweentiotropiumbromideandolodaterolonthecontractiletoneofhumanbronchi",fundedbyBoehringerIngelheimInternationalGmbH(2015)
- Componetedell’unitàdiricercadelDipartimentodiMedicinadeiSistemidell'UniversitàdiRoma "Tor Vergata" del Progetto TELETHON "Clinical efficacy of NIV and modafinil onexcessivedaytimesleepiness:amulticenter,randomized,double-blind,placebo-controlledclinicaltrialinDM1"
- Responsabiledelprogettodi ricercasullo"Studiosumodelloex-vivodibroncoumanodiinterazione farmacologicaesul sinergismotracorticosteroidi, LABAeLAMAnellediverseassociazioni",finanziatodaCHIESIfarmaceuticispa(2016)
- Principal investigator, Ricerca Scientifica di Ateneo 2015 "Consolidate the Foundations",progetto dal titolo" Human bronchial hyperresponsiveness in a human ex vivomodel ofdiabetesmellitus"
BREVETTI/INVENZIONI
2012 Software applicativo per smartphone, tablet e calcolatori elettronici, “COPDCoRi:
applicazione non invasiva per la stima e la previsione del rischio di patologia coronarica nei
pazientiaffettidabroncopneumopatiacronicaostruttiva(BPCO)”.(Autori:P.Rogliani,MGMatera,
FRomeo,L.Calzetta;depositatoallaSIAEn.2013001671)
19Aprile2017 PaolaRogliani
ATTIVITÀCLINICA
12/2000-12/2002 AttivitàassistenzialeinqualitàdiDirigentemedicodiIlivellopressoilRepartodiMalattiedell’ApparatoRespiratoriodellaDivisioneclinicizzatadiMalattieRespiratoriedirettadalProf.C.Saltini,UniversitàdeglistudidiRoma“TorVergata”,pressol’IRCCS“L.Spallanzani”Roma.
1/2003-07/2003 AttivitàassistenzialeinqualitàdiDirigentemedicodiIlivellopressol’AmbulatoriodiMalattiedell’ApparatoRespiratoriodellaDivisioneclinicizzatadiMalattieRespiratoriedirettadalProf.C.Saltini,UniversitàdeglistudidiRoma“TorVergata”,pressol’IRCCS“L.Spallanzani”Roma
1/2003-06/2004 ResponsabiledelDay-HospitaldedicatoalloStudiodelleInterstiziopatiePolmonaripressolaDivisioneclinicizzatadiMalattieRespiratorie,UniversitàdeglistudidiRoma“TorVergata”,pressol’IRCCS“L.Spallanzani”Roma.
7/2004-2007 Incaricoaifiniassistenzialipressol’ambulatoriodiMalattieRespiratoriedellaDisciplinadiMalattieRespiratoriedirettadalProf.C.Saltini,AreaFunzionaleAggregatadiMedicina,AziendaOspedalieraUniversitaria“PoliclinicoTorVergata”
1/2006-12/2007 ResponsabiledelServizioConsulenzePneumologichedellaDisciplinadiMalattieRespiratorie,AreaFunzionaleAggregatadiMedicina,AOU“PoliclinicoTorVergata”
11/2007-11/2011 ResponsabiledelDay-HospitaldedicatoalloStudiodelleInterstiziopatiePolmonariedell’ambulatoriodella“Fibrosipolmonareemalattierare”dellaUOCdiMalattieRespiratorie,AreaFunzionaleAggregatadiMedicina,AziendaOspedalieraUniversitaria“PoliclinicoTorVergata”
12/2011-Sett/2013 ResponsabiledelRepartodiMalattiedell’ApparatoRespiratoriodellaUOCdiMalattieRespiratoriePoliclincicoTorVergata,Roma
1/2006-presente Dirigentedell’UnitàOperativaSemplice(UOS)di“EndoscopiaRespiratoria”dellaUOCdiMalattieRespiratorie,DipartimentoClinicodiMedicina,“PoliclinicoTorVergata”
11/2015-presente Direttore(ff)dell’UnitàOperativaComplessa(UOC)diMalattieRespiratorie,DipartimentoClinicodiMedicina,“PoliclinicoTorVergata”
19Aprile2017 PaolaRogliani
ATTIVITÀDIDATTICA
2013-2015 Direttore/CoordinatoredellaScuoladispecializzazionein“MedicinadelloSport”UniversitàdeglistudidiRoma“TorVergata”
2015-presente Direttore/CoordinatoreScuoladiSpecializzazionein“Malattiedell’ApparatoRespiratorio”,UniversitàdegliStudidiRoma“TorVergata”
A.A.2004-presente Incaricod’insegnamentodiMalattiedell’ApparatoRespiratoriopressoilCorsodiLaureaSpecialisticainScienzedellaRiabilitazione,dell’UniversitàdegliStudidiRoma“TorVergata”
A.A.2005-presente Incaricod’insegnamentodiMalattiedell’ApparatoRespiratoriopressoilCorsodiLaureainScienzeInfermieristiche,dell’UniversitàdegliStudidiRoma“TorVergata”
A.A.2006-presente CoordinatoredelCorsoIntegratodi“Malattiedell’ApparatoRespiratorioeCardiovascolare”delCorsodiLaureaspecialisticainScienzeeTecnichedelleattivitàmotoriePreventiveedAdattate,dell’UniversitàdegliStudidiRoma“TorVergata”
A.A.2006-2015 Incaricod’insegnamentodiFisiopatologiaRespiratoria(modulo),CorsoIntegratoPatologiaSistematicaI,pressoilCorsodiLaureainMedicinaeChirurgia,dell’UniversitàdegliStudidiRoma“TorVergata”
A.A.2015-presente Incaricod’insegnamentodiMalattiedell’ApparatoRespiratorio,CorsoIntegratoPatologiaSistematicaI,pressoilCorsodiLaureainMedicinaeChirurgia,dell’UniversitàdegliStudidiRoma“TorVergata”
A.A.1995-1998 AttivitàdidatticaconseminarimonotematicisullaPatologiaRespiratoriapressolaScuoladiSpecializzazioneinEndocrinologiaelaScuoladiSpecializzazioneinGeriatria
A.A.2000-presente AttivitàtutorialeperlaformazionescientificaeclinicadeglistudentidelCorsodiLaureainMedicinaeChirurgia,UniversitàdegliStudidiRoma-“TorVergata”
A.A.2000-presente GuidanellaelaborazionedelletesidispecializzazioneedattivitàtutorialeperlaformazionescientificaeclinicadeglispecializzandidellaScuoladiMalattiedell’ApparatoRespiratoriodell’UniversitàdegliStudidiRoma“TorVergata”
19Aprile2017 PaolaRogliani
A.A.2000-presente Incaricod’insegnamentodiMetodologiaClinicaediMalattieRespiratoriepressolaScuoladiSpecializzazioneinMalattiedell’ApparatoRespiratoriodell’UniversitàdegliStudidiRoma“TorVergata”
A.A.2000-presente Incaricod’insegnamentodiMalattieRespiratoriepressolaScuoladiSpecializzazioneinEndocrinologiaeMalattieMetabolichedell’UniversitàdegliStudidiRoma“TorVergata”
A.A.2002-presente Incaricod’insegnamentopressolaScuoladiSpecializzazioneinGeriatriadell’UniversitàdegliStudidiRoma“TorVergata”
A.A.2006-presente Incaricod’insegnamentodiRiabilitazioneCardiorespiratoriapressolaScuoladiSpecializzazioneinCardiologiadell’UniversitàdegliStudidiRoma“TorVergata”
A.A.2006-2007 Incaricod’insegnamentodiMalattieRespiratoriepressolaScuoladiSpecializzazioneinMedicinadelloSportdell’UniversitàdegliStudidiRoma“TorVergata”
A.A.2007-presente Incaricod’insegnamentodiFisiopatologiaRespiratoriapressolaScuoladiSpecializzazioneinChirurgiaToracicadell’UniversitàdegliStudidiRoma“TorVergata”
A.A.2007-presente Incaricod’insegnamentodiFisiopatologiaRespiratoriapressolaScuoladiSpecializzazioneinMedicinaInternadell’UniversitàdegliStudidiRoma“TorVergata”
PARTECIPAZIONEALCOLLEGIODEIDOCENTIDIDOTTORATO
A.A.2006-2011 DottoratodiRicerca"FisiopatologiaSperimentaleeMedicinaMolecolare"UniversitàdegliStudidiROMA"TorVergata"
A.A.2011-presente DottoratodiRicerca"MedicinaSperimentaleedeiSistemi"UniversitàdegliStudidiROMA"TorVergata".
ATTIVITA’DIDATTICAUFFICIALEPRESSOATENEIESTERI
A.A.2009-2012 Incaricod’insegnamentodiMalattiedell’ApparatoRespiratorio,CorsoIntegratoPatologiaSistematicaI,pressoilCorsodiLaureainMedicinaeChirurgiaUniversità"NostraSignoradelBuonConsiglio",Tirana,Albania
19Aprile2017 PaolaRogliani
ATTIVITA’ISTITUZIONALEd’ATENEO
2013-presente MembrodelPresidioQualitàdiAteneo(PQA),MacroareadiMedicinaeChirurgia,UniversitàdegliStudidiROMA"TorVergata".
2016-presente Commissionepariteticadocenti/studenti,FacoltàdidiMedicinaeChirurgia,UniversitàdegliStudidiROMA"TorVergata".
2016-presente MembrodellaCommissioneperlaValorizzazionedeiRisultatidellaRicercaeperilTrasferimentoTecnologicoincomposizione'Brevetti',UniversitàdegliStudidiROMA"TorVergata".
19Aprile2017 PaolaRogliani
PUBBLICAZIONI1) MaioneF,IaccarinoF,SirignanoM,RoglianiP,DellaPietraF.“Studiodiunavariantediα1-
Antitripsina”.Acc.DiScienzaMedicheeChirurgiche(VolCXLVIIfeb.1993)
2) Rossi P. - Senis L. - Contini A. - Nardecchia B. - Rogliani P. - Bisogni V. - Rossi S.
“Osservazioni clinico-epidemiologiche sulla tubercolosi polmonare nei pazienti
extracomunitari ricoverati”. IgieneeSanitàPubblica,vol.52,n.4, luglio-agosto1996,pp.
271-280.
3) DiNardoP,FiaccaventoR,NataliA,MinieriM,SampaolesiM,FuscoA,JanmotC,CudaG,
CarboneA,RoglianiP,PeruzziG.“Embryonicgeneexpressioninnonoverloadedventricles
of hereditary hypertrophic cardiomyopathic hamsters”. Lab Invest. 1997 Nov;77(5):489-
502.
4) MineoTC,PompeoE,SimonettiG,SabatoAF,TuraniF,RoglianiP,DePadovaF,NofroniI.
“Unilateral thoracoscopic reduction pneumoplasty for asymmetric emphysema”. Eur J
CardiothoracSurg.1998Jul;14(1):33-9.
5) NovoradovskyA,BrantlyML,WaclawiwMA,ChaudharyPP,IharaH,QiL,EissaNT,Barnes
PM,GabrieleKM,EhrmantrautME,RoglianiP,MossJ.“Endothelialnitricoxidesynthaseas
a potential susceptibility gene in the pathogenesis of emphysema in alpha1-antitrypsin
deficiency”.AmJRespirCellMolBiol.1999Mar;20(3):441-7.
6) Mineo TC, Pompeo E, Rogliani P, Villaschi S, Pistolese C, Simonetti G. “Thoracoscopic
reduction pneumoplasty for severe emphysema: do pleural adhesions affect outcome?”
ThoracCardiovascSurg.1999Oct;47(5):288-92.
7) TesauroM,ThompsonWC,RoglianiP,QiL,ChaudharyPP,MossJ.“Intracellularprocessing
of endothelial nitric oxide synthase isoforms associated with differences in severity of
cardiopulmonary diseases: cleavage of proteinswith aspartate vs. glutamate at position
298”.ProcNatlAcadSciUSA.2000Mar14;97(6):2832-5
8) MineoTC,PompeoE,RoglianiP,DauriM,TuraniF,BolleroP,MagliocchettiN.“Effectof
lungvolumereductionsurgeryforsevereemphysemaonrightventricularfunction”.AmJ
RespirCritCareMed.2002Feb15;165(4):489-94.
9) AmicosanteM,BerrettaF,FranchiA,RoglianiP,DottiC,LosiM,DweikR,SaltiniC.“HLA-
DP-unrestricted TNF-alpha release in beryllium-stimulatedperipheral bloodmononuclear
cells”.EurRespirJ.2002Nov;20(5):1174-8.
19Aprile2017 PaolaRogliani
10) RoglianiP,AmicosanteM,BerrettaF,DottiC,BocchinoM,O'DonnellKM,SaltiniC.Roleof
theHLA-DPglu69andtheTNFalphaTNFalpha2genemarkersinsusceptibilitytoberyllium
hypersensitivity.IntJImmunopatholPharmacol.2004May-Aug;17(2Suppl):3-10
11) DottiC,D'ApiceMR,RoglianiP,NovelliG,SaltiniC,AmicosanteM.AnalysisofTNF-alpha
promoter polymorphisms in the susceptibility to beryllium hypersensitivity. Sarcoidosis
VascDiffuseLungDis.2004Mar;21(1):29-34)
12) PompeoE,MineoD,BolleroP,RoglianiP,AmbrogiV,MineoTC.Completion lobectomy
after bilateral lung volume reduction for emphysema: salvage option or fancy? J Thorac
CardiovascSurg.2004Apr;127(4):1212-4.
13) Pompeo E, Mineo D, Rogliani P, Sabato AF, Mineo TC. Feasibility and results of awake
thoracoscopic resection of solitary pulmonary nodules. Ann Thorac Surg. 2004
Nov;78(5):1761-8
14) MineoTC,PompeoE,MineoD,RoglianiP,LeonardisC,NofroniI.Resultsofunilaterallung
volumereductionsurgery inpatientswithdistinctheterogeneityofemphysemabetween
lungs.JThoracCardiovascSurg.2005Jan;129(1):73-9
15) Amicosante M, Berretta F, Rossman M, Butler RH, Rogliani P, van den Berg-Loonen E,
SaltiniC.IdentificationofHLA-DRPhebeta47asthesusceptibilitymarkerofhypersensitivity
to beryllium in individuals lacking the berylliosis-associated supratypic marker HLA-
DPGlubeta69.RespirRes.2005Aug14;6:94.
16) Cazzola M, Matera MG, Rogliani P, Page C. Treating systemic effects of COPD. Trends
PharmacolSci.2007Oct;28(10):544-50.
17) Cazzola M, Rogliani P, Curradi G. Bacterial extracts for the prevention of acute
exacerbationsinchronicobstructivepulmonarydisease:apointofview.RespirMed.2008
Mar;102(3):321-7.
18) Rogliani P, Mura M, Porretta MA and Saltini C. New perspectives in the treatment of
idiopathicpulmonaryfibrosis.TherapeuticAdvancesinRespiratoryDisease2008;2;75
19) RoglianiP,MuraM,MattiaP,FerlosioA,FarinelliG,MariottaS,GrazianoP,PezzutoG,Ricci
A, Saltini C, Orlandi A. HRCT and histopathologic evaluation of fibrosis and tissue
destruction in IPF associated with pulmonary emphysema. Respir Med. 2008
Dec;102(12):1753-61
20) CazzolaM,MuraM,SegretiA,MatteiMA,RoglianiP.
19Aprile2017 PaolaRogliani
Eosinophilicpneumoniainanasthmaticpatienttreatedwithomalizumabtherapy:forme-
frusteofChurg-Strausssyndrome?Allergy.2009Sep;64(9):1389-90.
21) MateraMG,CalzettaL,ParascandoloV,CurradiG,RoglianiP,CazzolaM.Relaxanteffectof
brainnatriureticpeptideinnonsensitizedandpassivelysensitizedisolatedhumanbronchi.
PulmPharmacolTher.2009Dec;22(6):478-82.
22) Cazzola M, Rogliani P, Curradi G, Segreti A, Ciaprini C, Pezzuto G, Saltini C. A pilot
comparisonofheliumdilutionandplethysmographiclungvolumestoassesstheimpactof
a long-actingbronchodilatoron lunghyperinflation inCOPD.PulmPharmacolTher.2009
Dec;22(6):522-5.
23) ComandiniA,Rogliani P,NunziataA, CazzolaM,CurradiG, Saltini C. Biomarkersof lung
damage associated with tobacco smoke in induced sputum. Respir Med. 2009
Nov;103(11):1592-613.
24) RoglianiP,CurradiG,MuraM,LauroD,FedericiM,GalliA,SaltiniC,CazzolaM.Metabolic
syndromeandriskofpulmonaryinvolvement.RespirMed.2010Jan;104(1):47-51.
25) RicciA,Mariotta S,Bronzetti E, BrunoP,Vismara L,DeDominicisC, LaganàB, PaoneG,
MuraM,RoglianiP,MastrangeldoM,SciacchitanoS,SaltiniC.SerumCA15-3isincreased
inpulmonaryfibrosis.SarcoidosisVascDiffuseLungDis.2009Jul;26(1):54-63.
26) SergiacomiG,BolacchiF,CadioliM,AngeliML,Fucci F,CruscoS,RoglianiP,Pezzuto G,
RomeoF,MarianoE,SimonettiG.Combinedpulmonaryfibrosisandemphysema:3Dtime-
resolvedMRangiographicevaluationofpulmonaryarterialmeantransittimeandtimeto
peakenhancement.Radiology.2010Feb;254(2):601-8.
27) CazzolaM,CalzettaL,BettoncelliG,NovelliL,CricelliC,RoglianiP.
Asthmaandcomorbidmedicalillness.EurRespirJ.2011Jul;38(1):42-9.
28) MateraMG,CalzettaL,RoglianiP,BardaroF,PageCP,CazzolaM.Evaluationoftheeffects
of the R- and S-enantiomers of salbutamol on equine isolated bronchi. Pulm Pharmacol
Ther.2011Apr;24(2):221-6.
29) CazzolaM,SegretiA,BettoncelliG,Calzetta L,CricelliC,PasquaF,RoglianiP.Change in
asthma and COPD prescribing by Italian general practitioners between 2006 and 2008.
PrimCareRespirJ.2011Sep;20(3):291-8.
30) PompeoE,RoglianiP,TacconiF,DauriM,SaltiniC,NovelliG,MineoTC;AwakeThoracic
Surgery Research Group. Randomized comparison of awake nonresectional versus
19Aprile2017 PaolaRogliani
nonawake resectional lung volume reduction surgery. J Thorac Cardiovasc Surg. 2012
Jan;143(1):47-54.e1.
31) Cazzola M, Calzetta L, Bettoncelli G, Cricelli C, Romeo F, Matera MG, Rogliani P.
Cardiovascular disease in asthma and COPD: A population-based retrospective cross-
sectionalstudy.RespirMed.2012Feb;106(2):249-56.
32) MuraM, Porretta MA, Bargagli E, Sergiacomi G, Zompatori M, Sverzellati N, Taglieri A,
Mezzasalma F, Rottoli P, Saltini C, Rogliani P. Predicting survival in newly diagnosed
idiopathicpulmonaryfibrosis:a3-yearprospectivestudy.EurRespirJ.2012Jul;40(1):101-
9.
33) CazzolaM,CalzettaL,RoglianiP,LauroD,NovelliL,PageCP,KanabarV,MateraMG.High
glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK
pathway.AmJRespirCellMolBiol.2012Oct;47(4):509-16.
34) CazzolaM,CapuanoA,RoglianiP,MateraMG.Bacteriallysatesasapotentiallyeffective
approach in preventing acute exacerbation of COPD. Curr Opin Pharmacol. 2012
Jun;12(3):300-8.
35) Matera MG, Calzetta L, Passeri D, Rogliani P, Orlandi A. Epithelial-smooth muscle
cooperation is needed for brain natriuretic peptide-dependent bronchorelaxant activity.
PulmPharmacolTher.2012Sep21.
36) CazzolaM,RoglianiP,SegretiA,MateraMG.AnupdateonbronchodilatorsinPhaseIand
IIclinicaltrials.ExpertOpinInvestigDrugs.2012Oct;21(10):1489-501.
37) CazzolaM,SegretiA,RoglianiP.Comparativeeffectivenessofdrugsforchronicobstructive
pulmonarydisease.DrugsToday(Barc).2012Dec;48(12):785-94.
38) Pompeo E, Rogliani P, Cristino B, Schillaci O, Novelli G, Saltini C. Awake Thoracoscopic
BiopsyofInterstitialLungDisease.AnnThoracSurg.2013Feb;95(2):445-52.
39) Cazzola M, Segreti A, Stirpe E, Puxeddu E, Ora J, Rogliani P, Matera MG. Effect of an
additionaldoseofindacaterolinCOPDpatientsunderregulartreatmentwithindacaterol.
RespirMed.2013Jan;107(1):107-11.
40) CazzolaM,SegretiA,CalzettaL,RoglianiP.
Comorbidities of asthma: current knowledge and future researchneeds. CurrOpinPulm
Med.2013Jan;19(1):36-41-
19Aprile2017 PaolaRogliani
41) RoglianiP,CalzettaL,RendinaEA,MassulloD,DauriM,RinaldiB,CapuanoA,MateraMG.
The influence of propofol, remifentanil and lidocaine on the tone of human bronchial
smoothmuscle.PulmPharmacolTher.2013Jun;26(3):325-
42) CazzolaM, Page CP,Rogliani P,MateraMG. β2-Agonist Therapy in Lung Disease. Am J
RespirCritCareMed.2013Apr1;187(7):690-6.
43) Segreti A, Fiori E, Calzetta L, SabatiniM, Segreti V,Rogliani P, CazzolaM. The effect of
indacaterolduringanacuteexacerbationofCOPD.PulmPharmacolTher.2013Apr8.
44) CazzolaM, Rogliani P, Ruggeri P, Segreti A, Proietto A, Picciolo S, MateraMG. Chronic
treatmentwithindacaterolandairwayresponsetosalbutamolinstableCOPD.RespirMed.
2013Jun;107(6):848-53.
45) CazzolaM, Rogliani P, MateraMG. Aclidinium bromide/formoterol fumarate fixed-dose
combination for the treatment of chronic obstructive pulmonary disease. Expert Opin
Pharmacother.2013Apr;14(6):775-81.
46) CazzolaM, Rogliani P, Ruggeri P, Segreti A, Proietto A, Picciolo S, MateraMG. Chronic
treatmentwithindacaterolandairwayresponsetosalbutamolinstableCOPD.RespirMed.
2013Jun;107(6):848-53.
47) PompeoE,DauriM;AwakeThoracicSurgeryResearchGroup.Isthereanybenefitinusing
awake anesthesia with thoracic epidural in thoracoscopic talc pleurodesis? J Thorac
CardiovascSurg.2013Aug;146(2):495-7.
48) CalzettaL,PasseriD,KanabarV,RoglianiP,PageC,CazzolaM,MateraMG,OrlandiA.Brain
Natriuretic Peptide Protects Against Hyperreactivityof Human Asthmatic Airway Smooth
MuscleviaanEpithelialCellDependentMechanism.AmJRespirCellMolBiol.2013Sep27.
49) CalzettaL,PageCP,SpinaD,CazzolaM,RoglianiP, FaccioloF,MateraMG.Effectof the
mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth
muscletone.JPharmacolExpTher.2013Sep;346(3):414-23.
50) CazzolaM,Calzetta L, LauroD,BettoncelliG,CricelliC,DiDanieleN,RoglianiP.Asthma
andCOPDinanItalianadultpopulation:roleofBMIconsideringthesmokinghabit.Respir
Med.2013Sep;107(9):1417-22.
51) RoglianiP,Ora J,CiapriniC,SenisL,StirpeE,CazzolaM.Effectof indacaterolonarterial
bloodgasesinpatientssufferingfromacuteexacerbationofCOPD.RespirMed.2013Nov
5.
19Aprile2017 PaolaRogliani
52) OraJ,CalzettaL,PezzutoG,SenisL,PaoneG,MariA,PortaloneS,RoglianiP,PuxedduE,
SaltiniC.A6MWTindextopredictO2flowcorrectingexerciseinducedSpO2desaturation
inILD.RespirMed.2013Dec;107(12):2014-21.
53) CazzolaM,RoglianiP,NovelliL,MateraMG.Inhaledcorticosteroidsforchronicobstructive
pulmonarydisease.ExpertOpinPharmacother.2013Dec;14(18):2489-99.
54) Segreti A, Fiori E, Calzetta L, SabatiniM, Segreti V,Rogliani P, CazzolaM. The effect of
indacaterol during an acute exacerbation of COPD. Pulm Pharmacol Ther. 2013
Dec;26(6):630-4.
55) CazzolaM,RoglianiP,RuggeriP,SegretiA,ProiettoA,PiccioloS,MateraMG.Chronic
treatmentwith indacaterol andairway response to salbutamol in stableCOPD.Respir
Med.2013Jun;107(6):848-53.
56) CazzolaM,RoglianiP,MateraMG.Aclidiniumbromide/formoterolfumaratefixed-dose
combination for the treatmentof chronicobstructivepulmonarydisease. ExpertOpin
Pharmacother.2013Apr;14(6):775-81.
57) Pompeo E, DauriM; Awake Thoracic Surgery ResearchGroup. Is there any benefit in
using awake anesthesia with thoracic epidural in thoracoscopic talc pleurodesis? J
ThoracCardiovascSurg.2013Aug;146(2):495-7.
58) CalzettaL,PageCP,SpinaD,CazzolaM,RoglianiP,FaccioloF,MateraMG.Effectofthe
mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth
muscletone.JPharmacolExpTher.2013Sep;346(3):414-23.
59) CazzolaM,CalzettaL,LauroD,BettoncelliG,CricelliC,DiDanieleN,RoglianiP.Asthma
and COPD in an Italian adult population: role of BMI considering the smoking habit.
RespirMed.2013Sep;107(9):1417-22.
60) OraJ,CalzettaL,PezzutoG,SenisL,PaoneG,MariA,PortaloneS,RoglianiP,PuxedduE,
Saltini C. A 6MWT index to predict O2 flow correcting exercise induced SpO2
desaturationinILD.RespirMed.2013Dec;107(12):2014-21.
61) Cazzola M, Rogliani P, Novelli L, Matera MG. Inhaled corticosteroids for chronic
obstructivepulmonarydisease.ExpertOpinPharmacother.2013Dec;14(18):2489-99
62) RoglianiP,OraJ,CiapriniC,SenisL,StirpeE,CazzolaM.
Effectofindacaterolonarterialbloodgasesinpatientssufferingfromacuteexacerbation
ofCOPD.RespirMed.2013Nov5.
63) MateraMG,CalzettaL,RoglianiP,CesarioA,CazzolaM.
19Aprile2017 PaolaRogliani
NewTreatmentsforCOPDintheElderly.CurrPharmDes.2014Mar14
64) MateraMG,RoglianiP,CazzolaM.
Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary
disease.ExpertOpinPharmacother.2014May;15(7):961-77
65) RoglianiP,CalzettaL,SegretiA,BarrileA,CazzolaM.Diabetesmellitusamongoutpatients
withCOPDattendingauniversityhospital.ActaDiabetol.2014Apr13
66) Calzetta L, Rogliani P, Cazzola M, Matera MG. Advances in asthma drug discovery:
evaluatingthepotentialofnasalcellsamplingandbeyond.ExpertOpinDrugDiscov.2014
Jun;9(6):595-607.Epub2014Apr22.
67) Segreti A, Stirpe E, Rogliani P, Cazzola M. Defining phenotypes in COPD: an aid to
personalizedhealthcare.MolDiagnTher.2014Aug;18(4):381-
68) CazzolaM, Calzetta L, Segreti A, Facciolo F,Rogliani P,MateraMG. Translational Study
SearchingforSynergybetweenGlycopyrroniumandIndacaterol.COPD.2014Sep15
69) MateraMG,Rogliani P, Calzetta L, CazzolaM. Phosphodiesterase Inhibitors for Chronic
ObstructivePulmonaryDisease:WhatDoestheFutureHold?Drugs.2014Oct10.
70) Segreti A, Calzetta L,Rogliani P, CazzolaM. Umeclidinium for the treatment of chronic
obstructivepulmonarydisease.ExpertRevRespirMed.2014Oct14:1-7.
71) MateraMG,RoglianiP,RinaldiB,CazzolaM. Umeclidiniumbromide+vilanterol for the
treatment of chronic obstructive pulmonary disease. Expert Rev Clin Pharmacol. 2015
Jan;8(1):35-41.
72) MateraMG,RoglianiP, CazzolaM. Indacaterol for the treatmentof chronicobstructive
pulmonarydisease.ExpertOpinPharmacother.2015Jan;16(1):107-15.
73) Cazzola M, Calzetta L, Page CP, Rogliani P, Facciolo F, Gavaldà A, Matera MG.
Pharmacological characterization of the interaction between aclidinium bromide and
formoterolfumarateonhumanisolatedbronchi.EurJPharmacol.2014Dec15;745:135-43
74) LipsiR,RoglianiP,CalzettaL,SegretiA,CazzolaM.Theclinicaluseofregenerativetherapy
inCOPD.IntJChronObstructPulmonDis.2014Dec12;9:1389-1396.eCollection2014.
75) MateraMG,CardaciV,CazzolaM,RoglianiP.
Safetyofinhaledcorticosteroidsfortreatingchronicobstructivepulmonarydisease.Expert
OpinDrugSaf.2015Jan5:1-9.
76) Rogliani P, Calzetta L, Ora J, Matera MG. Canakinumab for the treatment of chronic
obstructivepulmonarydisease.PulmPharmacolTher.2015Apr;31:15-27.
19Aprile2017 PaolaRogliani
77) MateraMG,RoglianiP,CazzolaM.QVA149(indacaterol/glycopyrronium)forthetreatment
of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2015
May;16(7):1079-90.
78) Calzetta L, Cazzola M, Page CP, Rogliani P, Facciolo F, Matera MG. Pharmacological
characterizationoftheinteractionbetweenthedualphosphodiesterase(PDE)3/4inhibitor
RPL554andglycopyrroniumonhumanisolatedbronchiandsmallairways.PulmPharmacol
Ther.2015Apr18.
79) Calzetta L, Luongo L, Cazzola M, Page C, Rogliani P, Facciolo F, Maione S, Capuano A,
RinaldiB,MateraMG.ContributionofsensorynervestoLPS-inducedhyperresponsiveness
ofhumanisolatedbronchi.LifeSci.2015Apr24.
80) Rogliani P, Calzetta L, Ora J, Lipsi R, Segreti A,MateraMG, CazzolaM. Pharmacological
assessmentof theonsetofactionofaclidiniumandglycopyrroniumversus tiotropium in
COPDpatientsandhumanisolatedbronchi.EurJPharmacol.2015Aug15;761:383-90
81) Cazzola M, Rogliani P, Sanduzzi A, Matera MG. Influence of ethnicity on response to
asthmadrugs.ExpertOpinDrugMetabToxicol.2015Jul;11(7):1089-97.
82) Ricciardolo FL, Blasi F, Centanni S, Rogliani P. Therapeutic novelties of inhaled
corticosteroidsandbronchodilatorsinasthma.PulmPharmacolTher.2015Aug;33:1-10
83) PompeoE,RoglianiP,PalombiL,OrlandiA,CristinoB,DauriM;AwakeThoracicSurgery
Research Group (ATSRG). The complex care of severe emphysema: role of awake lung
volumereductionsurgery.AnnTranslMed.2015May;3(8):108.
84) Pompeo E, Cristino B, Rogliani P, Dauri M; Awake Thoracic Surgery Research Group
(ATSRG).Urgentawakethoracoscopictreatmentofretainedhaemothoraxassociatedwith
respiratoryfailure.AnnTranslMed.2015May;3(8):112.
85) CazzolaM, Calzetta L,MateraMG,Muscoli S,Rogliani P, Romeo F. Chronic obstructive
pulmonarydiseaseandcoronarydisease:COPDCoRi,asimpleandeffectivealgorithmfor
predicting the risk of coronary artery disease in COPD patients. Respir Med. 2015
Aug;109(8):1019-25
86) CazzolaM,RoglianiP,MateraMG.Cardiovasculardisease inpatientswithCOPD.Lancet
RespirMed.2015Aug;3(8):593-5
87) RoglianiP,LucàGandLauroD.Chronicobstructivepulmonarydiseaseanddiabetes.COPD
ResearchandPractice2015Aug;1:3DOI:10.1186/s40749-015-0005-y
88) Basello K, Pacifici F, Capuani B, Pastore D, LombardoM, Ferrelli F, Coppola A, Donadel
19Aprile2017 PaolaRogliani
G,ArrigaR,SconocchiaG,BelliaA,RoglianiP,FedericiM,SbracciaP,LauroD,Della-Morte
D. Serum- and Glucocorticoid-Inducible Kinase (SGK)1 delay the onset of Endothelial
SenescencebyDirectlyInteractingwithhTERT.RejuvenationRes.2016Feb;19(1):79-89
89) CazzolaM, CoppolaA,Rogliani P,MateraMG.Novel glucocorticoid receptor agonists in
thetreatmentofasthma.ExpertOpinInvestigDrugs.2015Nov;24(11):1473-82.
90) Cazzola M, Rogliani P, Ora J, Matera MG. Olodaterol + tiotropium bromide for the
treatment of chronic obstructive pulmonary disease. Expert Rev Clin Pharmacol.
2015;8(5):529-39.
91) Cazzola M, Calzetta L, Ora J, Puxeddu E, Rogliani P, Matera MG. Searching for the
synergisticeffectbetweenaclidiniumandformoterol:Frombenchtobedside.RespirMed.
2015Oct;109(10):1305-11.
92) Cazzola M, Rogliani P, Matera MG. Escalation and De-escalation of Therapy in COPD:
Myths,RealitiesandPerspectives.Drugs.2015Sep;75(14):1575-85.
93) CazzolaM,CalzettaL,PageC,JardimJ,ChuchalinAG,RoglianiP,MateraMG.Influenceof
N-acetylcysteineonchronicbronchitisorCOPDexacerbations:ametaanalysis.EurRespir
Rev.2015Sep;24(137):451-61.
94) Rogliani P, Matera MG, Cazzola M. Fluticasone furoate/vilanterol combination for the
treatmentofCOPDandasthma.DrugsToday(Barc).2015Aug;51(8):469-78.
95) LiccardiG,SalzilloA,CalzettaL,PignattiP,RoglianiP.
Canpetkeepingbeconsidered theonlycriterionofexposure tocat/dogallergens in the
firstyearoflife?AllergolImmunopathol(Madr).2015Nov16.pii:S0301-0546(15)00121-4.
96) BaselloK,PacificiF,CapuaniB,PastoreD,LombardoMF,FerrelliF,CoppolaA,DonadelG,
ArrigaR,SconocchiaG,BelliaA,RoglianiP,FedericiM,SbracciaP,LauroD,Della-MorteD.
Serum-andGlucocorticoid-InducibleKinase1Delay theOnsetofEndothelial Senescence
byDirectly InteractingwithHumanTelomeraseReverseTranscriptase.RejuvenationRes.
2016Feb;19(1):79-89.
97) LiccardiG,SalzilloA,CalzettaL,PignattiP,RoglianiP.Canpetkeepingbeconsideredthe
only criterion of exposure to cat/dog allergens in the first year of life? Allergol
Immunopathol(Madr).2016Jul-Aug;44(4):387-8.
98) CazzolaM,CalzettaL,RoglianiP,PuxedduE,FaccioloF,MateraMG.Interactionbetween
corticosteroidsandmuscarinicantagonistsinhumanairways.PulmPharmacolTher.2016
Feb;36:1-9.
19Aprile2017 PaolaRogliani
99) LiccardiG,SalzilloA,CalzettaL,PiccoloA,RoglianiP.Howmanysystemicreactionstoskin
pricktestscouldbepreventableindefinedconditions?AnnAllergyAsthmaImmunol.2016
Feb;116(2):174.
100) CazzolaM,RoglianiP,OraJ,MateraMG.Treatmentoptionsformoderate-to-verysevere
chronicobstructivepulmonarydisease.ExpertOpinPharmacother.2016;17(7):977-88.
101) CalzettaL,RoglianiP,MateraMG,CazzolaM.ASystematicReviewWithMeta-Analysisof
Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. Chest. 2016
May;149(5):1181-96.
102) Matera MG, Rogliani P, Calzetta L, Cazzola M. Safety Considerations with Dual
BronchodilatorTherapyinCOPD:AnUpdate.DrugSaf.2016Jun;39(6):501-8.
103) Liccardi G, Salzillo A, Calzetta L, Piccolo A, Menna G, Rogliani P. Can the presence of
cat/dogathomebeconsideredtheonlycriterionofexposuretocat/dogallergens?Alikely
underestimated bias in clinical practice and in large epidemiological studies. Eur Ann
AllergyClinImmunol.2016Mar;48(2):61-4.
104) LiccardiG,SalzilloA,CalzettaL,PiccoloA,RoglianiP.Chroniccatallergenexposureandlow
sensitization: Possible limitations in patient selection? J Allergy Clin Immunol. 2016
May;137(5):1621-2.
105) Cazzola M, Calzetta L, Rogliani P, Matera MG. The discovery of roflumilast for the
treatment of chronic obstructive pulmonary disease. Expert Opin Drug Discov. 2016
Jul;11(7):733-44.
106) D'AntonioS,RoglianiP,PaoneG,AltieriA,AlmaMG,CazzolaM,PuxedduE.Anunusual
outbreakofnontuberculousmycobacteria inhospital respiratorywards:Associationwith
nontuberculous mycobacterial colonization of hospital water supply network. Int J
Mycobacteriol.2016Jun;5(2):244-7.
107) LiccardiG,SalzilloA,CalzettaL,OraJ,RoglianiP.Dogallergenimmunotherapyandallergy
tofurryanimals.AnnAllergyAsthmaImmunol.2016Jun;116(6):590.
108) RoglianiP,CalzettaL,CazzolaM,MateraMG.Drugsafetyevaluationofroflumilastforthe
treatmentofCOPD:ameta-analysis.ExpertOpinDrugSaf.2016Aug;15(8):1133-46.
109) Salvati,A.,Ora,J.,Donatucci,B.,Rogliani,P.Cardiopulmonaryexercisetestinathletesand
coronarydiseasesMedicinadelloSport69(2)June2016,289-296
110) CazzolaM,CalzettaL,PuxedduE,OraJ,FaccioloF,RoglianiP,MateraMG.Pharmacological
characterisation of the interaction between glycopyrronium bromide and indacaterol
19Aprile2017 PaolaRogliani
fumarate in human isolated bronchi, small airways and bronchial epithelial cells. Respir
Res.2016Jun13;17(1):70.
111) Liccardi G, Salzillo A, Calzetta L, Piccolo A, Rogliani P. Assessment of pet exposure by
questionnairesinepidemiologicalstudies(butalsoinclinicalpractice!):Whythequestions
shouldbesimplified?JAsthma.2016Nov;53(9):879-81.
112) Cazzola M, Ora J, Di Paolo A, Puxeddu E, Calzetta L, Rogliani P. Onset of action of
budesonide/formoterolSpiromax(®)comparedwithbudesonide/formoterolTurbuhaler(®)
inpatientswithCOPD.PulmPharmacolTher.2016Aug;39:48-53.
113) CazzolaM,Rogliani P. Dowe really need asthma-chronic obstructive pulmonary disease
overlapsyndrome?JAllergyClinImmunol.2016Oct;138(4):977-983.
114) LiccardiG,SalzilloA,CalzettaL,OraJ,CazzolaM,MateraMG,RoglianiP.Cananincreased
cholinergictoneconstituteapredictorofpositiveresponsetotiotropiuminpatientswith
moderateasthma?JAllergyClinImmunolPract.2016Jul-Aug;4(4):791-3.
115) Liccardi G, Salzillo A, Piccolo A, Calzetta L,Rogliani P. Dysfunction of small airways and
prevalence, airway responsiveness and inflammation in asthma: much more than small
particlesizeofpetanimalallergens.UpsJMedSci.2016Aug;121(3):196-7.
116) RoglianiP,CalzettaL,CapuaniB,FaccioloF,CazzolaM,LauroD,MateraMG.Glucagon-Like
Peptide 1 Receptor: A Novel Pharmacological Target for Treating Human Bronchial
Hyperresponsiveness.AmJRespirCellMolBiol.2016Dec;55(6):804-814.
117) CalzettaL,OrlandiA,PageC,RoglianiP,RinaldiB,RosanoG,CazzolaM,MateraMG.Brain
natriureticpeptide:Muchmorethanabiomarker.IntJCardiol.2016Oct15;221:1031-8.
118) CapuaniB,PacificiF,PastoreD,PalmirottaR,DonadelG,ArrigaR,BelliaA,DiDanieleN,
RoglianiP,AbeteP,SbracciaP,GuadagniF,LauroD,Della-MorteD.TheroleofepsilonPKC
in acute and chronic diseases: Possible pharmacological implications of its modulators.
PharmacolRes.2016Sep;111:659-67.
119) Rogliani P, Calzetta L, Cavalli F,MateraMG, CazzolaM. Pirfenidone, nintedanib and N-
acetylcysteineforthetreatmentofidiopathicpulmonaryfibrosis:Asystematicreviewand
meta-analysis.PulmPharmacolTher.2016Oct;40:95-103.
120) LiccardiG,SalzilloA,CalzettaL,CazzolaM,MateraMG,RoglianiP.Canbronchialasthma
withanhighlyprevalentairway (andsystemic)vagal tonebeconsideredan independent
asthmaphenotype?Possibleroleofanticholinergics.RespirMed.2016Aug;117:150-3.
121) BlasiF,PageC,RossoliniGM,PallecchiL,MateraMG,RoglianiP,CazzolaM.Theeffectof
19Aprile2017 PaolaRogliani
N-acetylcysteineonbiofilms:Implicationsforthetreatmentofrespiratorytractinfections.
RespirMed.2016Aug;117:190-7.
122) MateraMG,PageC,RoglianiP,CalzettaL,CazzolaM.TherapeuticMonoclonalAntibodies
fortheTreatmentofChronicObstructivePulmonaryDisease.Drugs.2016Sep;76(13):1257-
70.
123) Liccardi G, Calzetta L, Sapio C,Rogliani P. Occupational allergy to horse allergens:More
thanexposuretohorses!IntJOccupMedEnvironHealth.2016;29(5):721-3.
124) Liccardi G, Salzillo A, Calzetta L, Ora J, Rogliani P. Gastroesophageal reflux and COPD
exacerbations: Is cholinergic-mediated oesophago-bronchial reflex a possible link?
Respirology.2016Sep16
125) CazzolaM,Rogliani P. LABA/LAMA combinations instead of LABA/ICS combinationsmay
prevent or delay exacerbations of COPD in some patients. Evid Based Med. 2016
Dec;21(6):222.
126) RoglianiP,PuxedduE,CiapriniC,OraJ,OnoratoA,PezzutoG,CalzettaL,CazzolaM.The
TimeCourseofPulmonaryFunctionTestsinCOPDPatientswithDifferentLevelsofBlood
Eosinophils.BiomedResInt.2016;2016:4547953.
127) RoglianiP,OraJ,PuxedduE,CazzolaM.Airflowobstruction:isitasthmaorisitCOPD?IntJ
ChronObstructPulmonDis.2016Nov30;11:3007-3013.
128) LiccardiG,SalzilloA,CalzettaL,PiccoloA,PuxedduE,RoglianiP.IsAllergicSensitizationto
Siberian Hamster Preventable in High-Risk Individuals Who Are Already Sensitized or
ExposedtoFurryAnimals?JInvestigAllergolClinImmunol.2016;26(6):403-405.
129) TacconiF,RoglianiP,CristinoB,GilardiF,PalombiL,PompeoE;AwakeThoracicSurgery
ResearchGroup..Minimalistvideo-assistedthoracicsurgerybiopsyofmediastinaltumors.J
ThoracDis.2016Dec;8(12):3704-3710
130) CalzettaL,RoglianiP,OraJ,PuxedduE,CazzolaM,MateraMG.LABA/LAMAcombination
in COPD: a meta-analysis on the duration of treatment. Eur Respir Rev. 2017 Jan
17;26(143).
131) CazzolaM,CalzettaL,FaccioloF,RoglianiP,MateraMG.Pharmacologicalinvestigationon
theanti-oxidantandanti-inflammatoryactivityofN-acetylcysteineinanexvivomodelof
COPDexacerbation.RespirRes.2017Jan24;18(1):26
132) CazzolaM,OraJ,RoglianiP,MateraMG.Roleofmuscarinicantagonistsinasthmatherapy.
ExpertRevRespirMed.2017Mar;11(3):239-253
19Aprile2017 PaolaRogliani
133) Cazzola M, Calzetta L, Rogliani P, Matera MG. Tiotropium formulations and safety: a
networkmeta-analysis.TherAdvDrugSaf.2017Jan;8(1):17-30
134) Puxeddu E, Cavalli F, Pezzuto G, Teodori E, Rogliani P. Impact of pulmonary vascular
volume on mortality in IPF: is it time to reconsider the role of vasculature in disease
pathogenesisandprogression?EurRespirJ.2017Feb23;49(2)
135) Cazzola M, Calzetta L, Rogliani P, Matera MG. The Challenges of PrecisionMedicine in
COPD.MolDiagnTher.2017Feb28
136) Liccardi G, Calzetta L, Salzillo A, Apicella G, Cavalli F, Rogliani P. Is H1-antihistamine
(desloratadine 5 mg, orodispersible tablet) premedication in NSAID-associated urticaria
really safe and practicable in "real life"? J Allergy Clin Immunol Pract. 2017 Mar -
Apr;5(2):535
137) Rogliani P, Calzetta L, Coppola A, Cavalli F, Ora J, Puxeddu E, Matera MG, Cazzola M.
OptimizingdrugdeliveryinCOPD:Theroleofinhalerdevices.RespirMed.2017Mar;124:6-
14
138) Liccardi G, Calzetta L, Salzillo A, Puxeddu E, Rogliani P. Relationship between
oxytocin/vasopressinandlatexinobstetricsurgery:howtorecognize(andprevent)allergic
reactionsanddifferentiatethemfromsideeffects?JAllergyClinImmunolPract.2017Mar
9
139) LiccardiG,CalzettaL,SalzilloA,BilleriL,LucàG,RoglianiP.LettertotheEditor:Candog
allergenimmunotherapyreduceconcomitantallergicsensitizationtootherfurryanimals?
Apreliminaryexperience.EurAnnAllergyClinImmunol.2017Mar;49(2):92-96
140) CalzettaL,RoncadaP,diCaveD,BonizziL,UrbaniA,PistocchiniE,RoglianiP,MateraMG.
Pharmacological treatments in asthma-affected horses: A pair-wise and network meta-
analysis.EquineVetJ.2017Mar10
141) BraidoF, IlariaB,AlleriP,BacciE,BarbettaC,BellocchiaM,BenfanteA,BlasiF,BuccaC,
BuscetiMT,CentanniS,ColanardiMC,ContoliM,CorsicoA,D'AmatoM,DiMarcoF,Marco
D,FerrariM,FlorioG,FoisAG,FoschinoBarbaroMP,SilviaG,GirbinoG,GrossoA,Latorre
M,ManiscalcoS,MazzaF,MereuC,MolinengoG,Ora J,PaggiaroP,PatellaV,PelaiaG,
Pirina P, ProiettoA,Rogliani P, Santus P, ScichiloneN, Simioli F, Solidoro P, Terraneo S,
ZucconU,CanonicaGW.Asthmamanagement inaspecialistsetting:ResultsofanItalian
RespiratorySocietysurvey.PulmPharmacolTher.2017Mar21
142) CazzolaM,CalzettaL,RinaldiB,PageC,RosanoG,RoglianiP,MateraMG.Managementof
19Aprile2017 PaolaRogliani
Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases. Drugs.
2017Mar28
143) PicaF,CiottiM,MauriciM,BuèC,NardiP,LucàG,MoroniG,RoglianiP,PernoCF,VolpiA.
Clinical features and outcome of hospitalized patients with HSV-1 DNA in the lower
respiratorytract.NewMicrobiol.2017Apr3;40(2)
144) Liccardi G, Calzetta L, Salzillo A, Piccolo A, Pane G, Rogliani P. Can a better patient
phenotyping predict the efficacy of tiotropium in asthmatic adolescents? Expert Opin
Pharmacother.2017Apr11
Contributoinvolume(CapitolooSaggio)
• RoglianiP,SegretiA,CazzolaM(2014).Chapter:15.AdultCardiacConditions.In:RichardF.
Lockey,MD,DennisK.Ledford,MD,andWithWAO.(acuradi):OXFORDPRESS,Asthma.
Comorbidities,CoexistingConditions,andDifferentialDiagnosis.
• RoglianiP,CiapriniC(2013).ILPAZIENTEFUMATORE.In:BreviarioMedico.Pavia:Selecta
Medica
• Frasca L, Ambrogi V,Rogliani P, Saltini C and Pompeo E (2012). Awake Lung Biopsy for
InterstitialLungDisease.In(acuradi):EugenioPompeo,AwakeThoracicSurgery.p.105-
118,London:BenthamEbooks,ISBN:978-1-60805-288-2